MDSs is more commonly seen in men above 65years old. Various cytopenias, including anemia, may persist for months to years before the diagnosis is settled.
Dyspoiesis in normocellular or hypercellular bone marrow is the main feature of this disease and include:
Dyserythropoiesis: ineffective erythropoiesis results in anemia and reticulocytopenia; anisocytosis and poikilocytosis
Dysgranulocytopoiesis: Neutropenia; decreased or abnormal neutrophils.
Dysmegakaryocytopoiesis Thrombocytopenia; large platelets with abnormal contents.
Management of MDSs is usually conservative till leukemic transformation.
Supportive care includes packed red blood cell transfusion, platelet transfusion, treatment of infection etc.
Androgens, pyridoxine, folate, and danazol
High doses of erythropoietin (5000 to 10,000 U/day) is helpful in 10% to 20% of patients. Other growth factors
Cytotoxic agents like Low dose cytosar therapy or topotecan showed activity in the treatment of this disease.
Bone marrow transplantation (BMT) should be considered in patients younger than 45 years of age who have an HLA-compatible sibling.
New drugs like Vidaza have shown to be effective in decreasing the transfusion needs and providing better quality of life, however no long term control of the disease could be demonstrated till now.
To read more about Vidaza you can visit our web page:
http://www.doctorslounge.com/oncology/a ... _approval/
This answer does not substitute for direct medical consultation.
Dr. Safaa Mahmoud.
MB BCh, MSc Internal Medicine. MD Medical Oncology.
PhD Experimental Medicine and Biochemical Science.